Search details
1.
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Lancet
; 394(10215): 2155-2164, 2019 12 14.
Article
in English
| MEDLINE | ID: mdl-31813636
2.
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
Breast Cancer Res Treat
; 179(1): 161-171, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31605311
3.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 849-56, 2016 Feb 27.
Article
in English
| MEDLINE | ID: mdl-26686957
4.
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 857-65, 2016 Feb 27.
Article
in English
| MEDLINE | ID: mdl-26686960
5.
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Cancer Prev Res (Phila)
; 16(11): 631-639, 2023 11 01.
Article
in English
| MEDLINE | ID: mdl-37756580
6.
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
Front Oncol
; 13: 1139347, 2023.
Article
in English
| MEDLINE | ID: mdl-37305569
7.
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.
Cancer
; 118(22): 5614-22, 2012 Nov 15.
Article
in English
| MEDLINE | ID: mdl-22569841
8.
25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1.
Breast Cancer Res Treat
; 133(3): 1077-88, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22415479
9.
Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30.
NPJ Breast Cancer
; 8(1): 123, 2022 Nov 19.
Article
in English
| MEDLINE | ID: mdl-36402796
10.
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Am J Obstet Gynecol
; 205(6): 535.e1-5, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21872200
11.
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
J Clin Oncol
; 39(34): 3800-3812, 2021 12 01.
Article
in English
| MEDLINE | ID: mdl-34554865
12.
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
J Natl Cancer Inst
; 113(8): 1105-1108, 2021 08 02.
Article
in English
| MEDLINE | ID: mdl-33159444
13.
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.
NPJ Breast Cancer
; 7(1): 55, 2021 May 20.
Article
in English
| MEDLINE | ID: mdl-34016989
14.
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
J Clin Oncol
; 38(5): 444-453, 2020 02 10.
Article
in English
| MEDLINE | ID: mdl-31821109
15.
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
Breast Cancer Res Treat
; 113(2): 315-20, 2009 Jan.
Article
in English
| MEDLINE | ID: mdl-18302020
16.
The use of tamoxifen and raloxifene for the prevention of breast cancer.
Recent Results Cancer Res
; 181: 113-9, 2009.
Article
in English
| MEDLINE | ID: mdl-19213563
17.
Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey.
Contemp Clin Trials Commun
; 10: 100-104, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-30023443
18.
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
J Clin Oncol
; 35(35): 3942-3948, 2017 Dec 10.
Article
in English
| MEDLINE | ID: mdl-29072977
19.
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA
; 295(23): 2727-41, 2006 Jun 21.
Article
in English
| MEDLINE | ID: mdl-16754727
20.
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.
Cancer Epidemiol Biomarkers Prev
; 25(1): 51-9, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26545405